Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. (not Eyepoint, Inc.) on March 13, 2014. The report details a registered direct offering of common stock entered into on the same date.
Key Financial Metrics
- Gross Proceeds: Approximately $7.0 million.
- Shares Issued: 1.7 million shares of common stock.
- Price Per Share: $4.11.
- Placement Agent: Northland Securities, Inc. (sole agent).
- Expected Closing Date: On or about March 18, 2014.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event is the execution of a securities purchase agreement with RA Capital to raise capital. This represents a significant change in the company's capital structure and cash position pending the closing of the transaction.
Outlook and Use of Proceeds
Management intends to use the proceeds from the offering for the following purposes:
- Accelerate the Tethadur program.
- Fund clinical trials for posterior uveitis.
- General corporate purposes.
A shelf registration statement has been declared effective by the SEC, and a prospectus supplement will be filed.
Investor Verification Checklist
- Verify the closing of the transaction on or about March 18, 2014.
- Confirm the final net proceeds after deducting placement agent fees and offering expenses.
- Review the attached Securities Purchase Agreement (Exhibit 99.1) for specific terms and conditions.
- Monitor the status of the Tethadur program and posterior uveitis clinical trials.